PeriodontitisBack

PeriodontitisBack

Periodontitis: A Dynamic Pathology

Periodontitis Manifests at Both the Microbial and
Clinical Levels1,2

chronic periodontitis disease tooth bacteria

Periodontitis is a chronic bacterial infection caused by microbial plaque, also called dental biofilm, that grows on the tooth’s surface and below the gingival margin. 

When dental biofilm irritates the gingiva, it breaks down the tissue and bone supporting the dentition. Left untreated, periodontitis, an oral infection, may ultimately increase periodontal pocket depth.3 This may also lead to tissue damage, gingival recession, and the spread of infection to healthy sites.3   

This subgingival biofilm is an epithelial cell-associated biofilm, lining the epithelial surface of the pocket. This dental biofilm contains primarily spirochetes and gram-negative bacterial species. Three of the most prominent species are:2

  • P. gingivalis
  • T. denticola
  • T. forsythia

These species belong to a class known as red complex bacteria (RCB) and have been detected in large numbers in periodontal pockets, and in epithelial cell-associated biofilms.2


Periodontal Disease Progression


  • Begins with an unhealthy balance of bacteria within the dental biofilm2
  • May lead to an oral infection which may ultimately contribute to increased pocket depth3
  • May also spread to healthy sites3
  • May lead to a range of risks and consequences if left untreated

Find out how adding ARESTIN® at the time of SRP may improve clinical outcomes for periodontal patients.

REFERENCES: 1. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL. Microbial complexes in subgingival plaque. J Clin Periodontol. 1998;25:134-144. 2. Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000. 2002;28:12-55. 3. Page RC. Periodontal diseases: a new paradigm. J Dent Educ. 1998;62(10):812-821. 4. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg. Prescribing Information. Horsham, PA: OraPharma, Inc.; 2011.

ARESTIN® is active against microorganisms associated with periodontal disease.4

INDICATION
ARESTIN® (minocycline HCl) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION
ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please read the Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

MyArestinTM is a trademark and ARESTIN® is a registered trademark of OraPharma, Inc.

This site is published by OraPharma, Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

Manufactured for OraPharma, Inc. ©OraPharma, Inc. 2013   A-1373-12   01/13